Biotechs fare relatively well amidst share collapse
Interviewee/Contributor
William Ellington
Organisation
MedNous
Stock market performance
Welcome to the Euro-Nasdaq waltz
Interviewee/Contributor
William Ellington
Organisation
MedNous
European biotechs narrowly ahead
Interviewee/Contributor
William Ellington
Organisation
MedNous
Investors show caution about biotechs
Interviewee/Contributor
William Ellington
Organisation
MedNous
Partial recovery of biotechs
Interviewee/Contributor
William Ellington
Organisation
MedNous
2018 Fourth quarter stock market review
Interviewee/Contributor
William Ellington
Organisation
MedNous
European biotechs pause during Q3
Interviewee/Contributor
William Ellington
Organisation
MedNous
Biotechs in Q2: For now, the trend is down
Interviewee/Contributor
William Ellington
Organisation
Evernow Publishing Ltd
European biotechs mixed in quarter
Interviewee/Contributor
William Ellington
Why pharma is paying a premium for assets
Interviewee/Contributor
Tim Sturgeon and Martin Gouldstone
Organisation
Results Healthcare